Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Millennium Pharmacon International Tbk's quarterly other current liabilities
increased
from Dec. 2025 (Rp89,331 Mil) to Mar. 2026 (Rp97,348 Mil) and
increased
from Mar. 2026 (Rp97,348 Mil) to Jun. 2026 (Rp113,079 Mil).
PT Millennium Pharmacon International Tbk's annual other current liabilities
increased
from Dec. 2023 (Rp62,905 Mil) to Dec. 2024 (Rp76,429 Mil) and
increased
from Dec. 2024 (Rp76,429 Mil) to Dec. 2025 (Rp89,331 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk Other Current Liabilities Chart
PT Millennium Pharmacon International Tbk Annual Data
PT Millennium Pharmacon International Tbk Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of Rp113,079 Mil mean?
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a Other Current Liabilities of Rp113,079 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PT Millennium Pharmacon International Tbk.
Is PT Millennium Pharmacon International Tbk's Other Current Liabilities too high?
PT Millennium Pharmacon International Tbk's current Other Current Liabilities is Rp113,079 Mil. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's Other Current Liabilities compare to MCK and COR?
PT Millennium Pharmacon International Tbk's Other Current Liabilities of Rp113,079 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Distribution company?
A good Other Current Liabilities depends on the Medical Distribution industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PT Millennium Pharmacon International Tbk. PT Millennium Pharmacon International Tbk's current Other Current Liabilities is Rp113,079 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp171.08, compared to a current price of Rp198.00 — trading 15.7% above its estimated fair value. The current Other Current Liabilities is Rp113,079 Mil. PT Millennium Pharmacon International Tbk's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current Other Current Liabilities is Rp113,079 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp198.00 is trading 15.7% above its estimated GF Value™ of Rp171.08.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Modestly Overvalued.
Key valuation signals for ISX:SDPC:
Other Current Liabilities: Rp113,079 Mil
GF Value™: Rp171.08 vs. price of Rp198.00 (15.7% above fair value)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
78GF Score
Get the complete analysis for ISX:SDPC
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
